Panic attack test: panic attack vs panic disorder

What is a panic attack: DSM-5 / ICD-11 definition

The query "panic attack test" attracts roughly 569 monthly impressions on the head-term and ~900 in the broader cluster with "anxiety", "online", "anxiety disorder". The audience is mixed: people seeking to understand what they experience (do I have panic? how serious is it?), and wanting a validated assessment instrument. The main confusion is conceptual: a panic attack and panic disorder are not the same thing.

DSM-5 (APA 2013) defines a panic attack as an abrupt surge of intense fear or discomfort peaking within minutes, with 4+ of 13 symptoms: heart palpitations, sweating, trembling, shortness of breath, choking sensation, chest pain, nausea, dizziness, chills or heat, paresthesias, derealization / depersonalization, fear of losing control, fear of dying. Typical duration — 5–20 minutes, peak ≈ 10 minutes. It is an event that can occur in isolation (isolated panic attack) or in the context of many mental conditions (GAD, PTSD, depression, OCD, specific phobia).

Panic disorder is a separate diagnosis: recurrent unexpected panic attacks plus ≥1 month of persistent worry about the next attack OR significant behavioural change in response to attacks (avoidance of places or situations). ICD-11 (WHO, in effect from 2022) under code 6B01 uses a similar definition. The key word is unexpected: attacks in panic disorder occur without an obvious trigger. If attacks happen predictably in response to a specific stimulus (flight, elevator, social situation), that is specific phobia or social anxiety, not panic disorder.

Panic attack vs panic disorder vs other entities

Differential diagnosis is the main obstacle to self-screening. The same phenomenological "panic episode" can belong to several different clinical entities, each with its own treatment of choice. Five typical scenarios:

• 1. Isolated panic attack(s). One or a few episodes in life in response to high-stress events, without recurrent unexpected attacks and without significant anticipatory anxiety. The most common form (22.7% lifetime). Usually does not require panic-disorder-specific therapy; psychoeducation plus work with the specific stressor is useful.
• 2. Panic disorder (DSM-5 / ICD-11). Recurrent unexpected attacks + persistent worry or behavioural change ≥ 1 month. With agoraphobia (1.1%) or without (3.7%). This is a diagnosis — it requires evidence-based treatment (see s6).
• 3. Panic attacks within GAD. Attacks occur at the peak of generalised anxiety and are usually predictable under stress. GAD-7 ≥ 10 is a screening marker. Treatment focus is GAD, not panic.
• 4. Panic in PTSD. Attacks triggered by trauma cues (sound, smell, a situation reminiscent of the trauma). This is a flashback or dissociative episode, not panic disorder. See screening via PCL-5. Treatment focus is trauma-focused, not panic-focused CBT.
• 5. Panic in severe MDD. Attacks during an episode of severe depression. Often comorbid (see s5). Screening via PHQ-9 ≥ 15; treatment prioritises depression.

A separate category is medical mimics. Symptoms identical to a panic attack can be produced by cardiac arrhythmia, hyperthyroidism, hypoglycaemia, asthma exacerbation, pheochromocytoma, or substance reactions (caffeine intoxication, withdrawal). A first-time panic attack is an indication for medical workup within 24 hours, especially with chest pain, shortness of breath, or in the absence of an obvious psychological context. Roy-Byrne, Craske & Stein (2006, Lancet, 368(9540):1023–1032) emphasise this in a seminar review.

Screening instruments: PDSS, PAS, PHQ-PD

Panic disorder has three main validated instruments, each covering a different task.

PDSS (Panic Disorder Severity Scale) — Shear, Brown, Barlow et al. (1997, Am J Psychiatry, 154(11):1571–1575). 7 items, clinician-rated, each item 0–4, total 0–28. The subsequent replication (Shear, Rucci, Williams et al. 2001, J Psychiatr Res, 35(5):293–296) on N=104 confirmed: cut-off ≥8 discriminates current panic disorder with sensitivity 83.3% / specificity 64.0%. PDSS-SR is the self-report version (Houck, Spiegel, Shear & Rucci 2002, Depress Anxiety, 15(4):183–185): Cronbach α = 0.917, test-retest ICC = 0.81. Psychometrically equivalent to the clinician-rated. Yamamoto et al. (2004, Depress Anxiety, 20(1):17–22, cross-cultural validation in a Japanese sample) proposed severity bands: ≤10 mild, 11–15 moderate, ≥16 severe.

PAS (Panic and Agoraphobia Scale) — Bandelow (1995, Int Clin Psychopharmacol, 10(2):73–81). Covers 5 domains: panic attacks, phobic avoidance, anticipatory anxiety, impairment in social / work, health-related concerns. ≈ 10 minutes to complete, observer-rated and self-report versions available. PHQ-PD is the panic module of PRIME-MD/PHQ (Spitzer, Kroenke & Williams 1999, JAMA, 282(18):1737–1744). PHQ performance in primary care: κ = 0.65 vs mental-health-professional diagnosis, accuracy 85%, sensitivity 75%, specificity 90%. Convenient for primary care.

A PubMed search as of May 2026: no peer-reviewed Russian-language validation of PDSS or PAS has been published. This is an honest gap — clinicians in Russia use the English originals with their own translation or work with adjacent validated instruments (see s4). WFSBP 2022 guidelines (Bandelow, Allgulander, Baldwin et al., World J Biol Psychiatry, 24(2):79–117) include two Russian co-authors from the Bekhterev Center in St. Petersburg — meaning the international consensus on panic disorder includes Russian clinical input at the guideline level.

A practical workflow for Russian-speaking audiences

In the absence of a peer-reviewed RU validation of panic-specific scales, a pragmatic workflow for self-screening and first-pass assessment looks like this:

• Step 1 — GAD-7 (Spitzer 2006, validated for the Russian-speaking population via cross-cultural extensions, present in the Soveria catalogue). Baseline anxiety 0–21. ≥10 = clinical concern, ≥15 = severe. GAD-7 is not panic-specific but reflects generalised anxiety burden.
• Step 2 — DSM-5 panic checklist: 4+ of 13 symptoms during an attack peaking in minutes. Self-administered, takes 2 minutes. Helps distinguish "panic" from health anxiety or generalised worry without a physiological surge.
• Step 3 — characterise the attacks: expected or unexpected? Recurrent or isolated? Is there persistent worry ≥ 1 month between them? This is the decision tree of the differential. Recurrent unexpected + worry ≥ 1 month = panic disorder pattern.
• Step 4 — clinician for finalisation. Self-screening gives a probability signal. Diagnosis is made by a clinician across the totality: clinical interview + DSM-5 criteria + medical workup to exclude mimics. Soveria provides a baseline GAD-7 and structured input for the clinician; PDSS-SR can be applied by the clinician afterwards.

The core principle: a positive screen is not a diagnosis. Self-report instruments signal probability — they do not confirm a diagnosis. This principle is general to all valid psychometrics in a clinical context.

Comorbidity: panic is rarely isolated

Kessler et al. (2006) in NCS-R showed: panic disorders, like most anxiety-spectrum conditions, have a high level of comorbidity with other DSM-IV disorders. About half of people with panic disorder also have lifetime MDD; high rates of comorbid social anxiety, GAD, PTSD, and substance use disorder. Isolated panic attacks (without disorder) also significantly increase the risk of comorbid pathology, but to a lesser degree than panic disorder.

What most commonly co-occurs with panic disorder — in clinical samples and epidemiological surveys:

• Major Depressive Disorder (~50% lifetime) — the most frequent comorbid, substantially worsens functioning and elevates suicide risk. Screening: PHQ-9, BDI-II as a mandatory part of assessment
• Other anxiety disorders (social anxiety, GAD, specific phobia) — high overlap. GAD-7 covers GAD at minimum; social anxiety requires separate screening (SPIN, LSAS)
• PTSD (~20%) — especially with childhood trauma in the history. Screening via PCL-5; trauma-focused therapy (see trauma screening) before panic-focused CBT
• Substance use disorders (~30%) — alcohol in particular. Often self-medication for anxiety. AUDIT for screening; concurrent treatment of substance use + panic

Thibodeau, Welch, Sareen & Asmundson (2013, Depression and Anxiety, 30(10):947–954, N=43,935 in NCS-R + NESARC) after propensity-score matching on dysthymia, MDD, alcohol/SUD, bipolar I/II and all other anxiety disorders showed: each anxiety disorder, including panic disorder with / without agoraphobia, is independently associated with lifetime suicide attempts (OR 3.57–6.64 in NCS-R; 3.03–7.00 in NESARC). That means panic disorder is an independent suicide risk factor, not only via comorbid depression. Screening for suicidal ideation is a mandatory part of assessment.

What works empirically in treatment

The treatment evidence for panic disorder is among the strongest in the anxiety spectrum. Pompoli, Furukawa, Efthimiou et al. (2018, Psychological Medicine, 48(12):1945–1953) performed a component network meta-analysis on 72 RCTs and 4,064 participants — the most comprehensive analysis of CBT components for panic disorder to date. Mitte (2005, J Affect Disord, 88(1):27–45, 124 studies) previously showed that (C)BT is at least as effective as pharmacotherapy in panic disorder. WFSBP 2022 guidelines (Bandelow et al., World J Biol Psychiatry, 24(2):79–117), based on evaluation of 1,007 RCTs, state directly: SSRIs and SNRIs are first-line medications, CBT is the first-line psychotherapy.

What Pompoli 2018 component-NMA showed specifically. Interoceptive exposure + face-to-face setting yield the best efficacy and acceptability in CBT for panic disorder. Muscle relaxation and virtual-reality exposure are, conversely, significantly lower in efficacy. Breathing retraining and in vivo exposure improve acceptability with small effect on efficacy. The difference between the most-vs-least efficacious CBT package in odds of remission is OR 7.69 (95% CrI 1.75–33.33): nearly an 8-fold gap between a well-built protocol and a poor one.

Practical implication: the label "CBT" covers very different protocols, and quality matters. Structured CBT with face-to-face interoceptive exposure is the gold standard. Benzodiazepines have efficacy in short-term cessation of panic attacks, but WFSBP 2022 and all major guidelines (APA, NICE, BAP) do not recommend them as long-term treatment because of dependence and cognitive-impairment risks. Combination of CBT + SSRI usually outperforms monotherapy in severe panic disorder with agoraphobia.

When to reach out: medical workup and red flags

Specific escalation criteria — grounded in clinical guidelines and epidemiological evidence:

• First-time panic attack → medical workup within 24 hours. Especially with chest pain, shortness of breath. The goal is to rule out medical mimics: cardiac arrhythmia, hyperthyroidism, hypoglycemia, asthma exacerbation, pheochromocytoma. This is not "all in your head" — the physiological surge is real and warrants verification
• Recurrent unexpected attacks + persistent worry ≥1 month → consultation with a clinician. This is the panic-disorder pattern and evidence-based treatment works; delay leads to deterioration in most people
• Avoidance behaviour beyond specific triggers (agoraphobia: fear of leaving home, using transport, being in a crowd) → clinician immediately. Agoraphobia with panic disorder is associated with 86.3% moderate-to-severe PDSS severity (Kessler 2006)
• Any active suicidal thoughts with plan or intent → immediate contact with a specialist, crisis line, emergency department. Panic disorder by itself increases lifetime risk of suicide attempts by 3.6–7× (Thibodeau 2013), independently of comorbid depression. See decision tree for escalation

Sources / Источники
Kessler R.C., Chiu W.T., Jin R., Ruscio A.M., Shear K., Walters E.E. (2006). The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 63(4), 415–424. · Roy-Byrne P.P., Craske M.G., Stein M.B. (2006). Panic disorder. Lancet, 368(9540), 1023–1032. · Shear M.K., Brown T.A., Barlow D.H., et al. (1997). Multicenter collaborative panic disorder severity scale. Am J Psychiatry, 154(11), 1571–1575. · Shear M.K., Rucci P., Williams J., et al. (2001). Reliability and validity of the Panic Disorder Severity Scale: replication and extension. J Psychiatr Res, 35(5), 293–296. · Houck P.R., Spiegel D.A., Shear M.K., Rucci P. (2002). Reliability of the self-report version of the Panic Disorder Severity Scale. Depress Anxiety, 15(4), 183–185. · Yamamoto I., Nakano Y., Watanabe N., et al. (2004). Cross-cultural evaluation of the Panic Disorder Severity Scale in Japan. Depress Anxiety, 20(1), 17–22. · Bandelow B. (1995). Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol, 10(2), 73–81. · Spitzer R.L., Kroenke K., Williams J.B. (1999). Validation and utility of a self-report version of PRIME-MD. JAMA, 282(18), 1737–1744. · Pompoli A., Furukawa T.A., Efthimiou O., et al. (2018). Dismantling cognitive-behaviour therapy for panic disorder: a systematic review and component network meta-analysis. Psychol Med, 48(12), 1945–1953. · Mitte K. (2005). A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder. J Affect Disord, 88(1), 27–45. · Bandelow B., Allgulander C., Baldwin D.S., et al. (2022). WFSBP guidelines for treatment of anxiety, OCD and PTSD — Version 3. Part I: Anxiety disorders. World J Biol Psychiatry, 24(2), 79–117. · Thibodeau M.A., Welch P.G., Sareen J., Asmundson G.J. (2013). Anxiety disorders are independently associated with suicide ideation and attempts. Depress Anxiety, 30(10), 947–954. · Bandelow B., Michaelis S. (2015). Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci, 17(3), 327–335. · Kessler R.C., Berglund P., Demler O., et al. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the NCS-R. Arch Gen Psychiatry, 62(6), 593–602. · American Psychiatric Association (2013). DSM-5. · World Health Organization (2022). ICD-11, code 6B01.